The corporate registered a income of ₹7,580 crore within the quarter as in opposition to ₹6,473 within the comparable quarter final 12 months, exhibiting a development of 17.1 per cent.
For the monetary 12 months 2023-24, the corporate reported a internet revenue of ₹3,173 crore (₹1,927 crore) on a income of ₹29,002 crore (₹24,855 crore).
- Additionally learn: Dr Reddy’s, Solar Pharma, Aurobindo recall merchandise in US
The US formulations (excluding Puerto Rico) income within the quarter went up by 21.6 per cent 12 months on 12 months to ₹3,588 crore, whereas Europe formulations income contributed ₹1,832 crore.
The corporate spent ₹392 crore or 5.2 per cent of its fourth quarter income on analysis and growth.
The corporate mentioned it obtained last approval for 17 ANDAs (Abbreviated new drug software), together with 4 specialty and injectable merchandise from the USFDA (US Meals and Drug Administration).
“We’re delighted to report a robust efficiency for the quarter and the 12 months, supported by the
- Additionally learn: Aurobindo Pharma will get tax demand of ₹13 crore, together with curiosity and penalties
enlargement into the brand new markets, product launches and steady pricing. Our improved capability utilisation has led to larger working efficiencies,” Okay Nithyananda Reddy, Vice-Chairman and Managing Director of Aurobindo Pharma, mentioned.
“We’re assured of constant our development within the upcoming 12 months, whereas stabilizing the operations of the not too long ago commercialised amenities,” he mentioned.
#Aurobindo #Pharma #PAT #crore